Population pharmacokinetics of anidulafungin in critically ill patients

S. Luque; W. Hope; N. Campillo; R. Muñoz-Bermúdez; L. Sorli; J. Barceló-Vidal; E. González-Colominas; F. Alvarez-Lerma; J. R. Masclans; M. Montero; J. P. Horcajada; S. Graua

doi:10.1128/AAC.00378-19

Population pharmacokinetics of anidulafungin in critically ill patients

S. Luque, W. Hope, N. Campillo, R. Muñoz-Bermúdez, L. Sorli, J. Barceló-Vidal, E. González-Colominas, F. Alvarez-Lerma, J. R. Masclans, M. Montero, J. P. Horcajada, S. Graua

Department of Medicine

Research output: Contribution to journal › Article › Research

15 Citations (Scopus)

Abstract

Copyright © 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.

Original language	English
Article number	e00378-19
Journal	Antimicrobial Agents and Chemotherapy
Volume	63
Issue number	7
DOIs	https://doi.org/10.1128/AAC.00378-19
Publication status	Published - Jul 2019

Keywords

Anidulafungin
Candida
Critical care unit
Monte Carlo simulation
Pharmacokinetics/pharmacodynamics

Access to Document

10.1128/AAC.00378-19

Cite this

Luque, S., Hope, W., Campillo, N., Muñoz-Bermúdez, R., Sorli, L., Barceló-Vidal, J., González-Colominas, E., Alvarez-Lerma, F., Masclans, J. R., Montero, M., Horcajada, J. P., & Graua, S. (2019). Population pharmacokinetics of anidulafungin in critically ill patients. Antimicrobial Agents and Chemotherapy, 63(7), Article e00378-19. https://doi.org/10.1128/AAC.00378-19

@article{e2272bee17e542afae2fa452491edd3f,

title = "Population pharmacokinetics of anidulafungin in critically ill patients",

abstract = "Copyright {\textcopyright} 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.",

keywords = "Anidulafungin, Candida, Critical care unit, Monte Carlo simulation, Pharmacokinetics/pharmacodynamics",

author = "S. Luque and W. Hope and N. Campillo and R. Mu{\~n}oz-Berm{\'u}dez and L. Sorli and J. Barcel{\'o}-Vidal and E. Gonz{\'a}lez-Colominas and F. Alvarez-Lerma and Masclans, {J. R.} and M. Montero and Horcajada, {J. P.} and S. Graua",

note = "Copyright {\textcopyright} 2019 American Society for Microbiology.",

year = "2019",

month = jul,

doi = "10.1128/AAC.00378-19",

language = "English",

volume = "63",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Population pharmacokinetics of anidulafungin in critically ill patients

AU - Luque, S.

AU - Hope, W.

AU - Campillo, N.

AU - Muñoz-Bermúdez, R.

AU - Sorli, L.

AU - Barceló-Vidal, J.

AU - González-Colominas, E.

AU - Alvarez-Lerma, F.

AU - Masclans, J. R.

AU - Montero, M.

AU - Horcajada, J. P.

AU - Graua, S.

PY - 2019/7

Y1 - 2019/7

N2 - Copyright © 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.

AB - Copyright © 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.

KW - Anidulafungin

KW - Candida

KW - Critical care unit

KW - Monte Carlo simulation

KW - Pharmacokinetics/pharmacodynamics

UR - http://www.mendeley.com/research/population-pharmacokinetics-anidulafungin-critically-ill-patients

U2 - 10.1128/AAC.00378-19

DO - 10.1128/AAC.00378-19

M3 - Article

C2 - 31061150

SN - 0066-4804

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

M1 - e00378-19

ER -

Population pharmacokinetics of anidulafungin in critically ill patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this